Click here to close now.

SYS-CON MEDIA Authors: Ian Goldsmith, Ed Featherston, Elizabeth White, Pat Romanski, Liz McMillan

News Feed Item

Analysis of the US Retinal Therapeutics Market

NEW YORK, Jan. 7, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Analysis of the US Retinal Therapeutics Market
http://www.reportlinker.com/p01936265/Analysis-of-the-US-Retinal-Therapeutics-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Improvements in Administration and Efficacy Drive Growth

Since the introduction of Lucentis in 2006, vascular endothelial growth factor (VEGF) antagonists have become the clear choice in treatment for age related macular degeneration, diabetic macular edema, and retinal vein occlusion due to their high efficacy and safety. This research service evaluates the US market for the pharmaceutical management of AMD, DME, and RVO from 2009 to 2017, with 2012 as the base year. Segmentation by disorder is provided. Included are products on the market, products in development, and patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed.

Methodology

•The information contained in this research service was derived from a variety of relevant primary and secondary sources.
•Secondary data sources include company publications (annual reports, US Securities and Exchange Commission (SEC) filings, investor presentations, earnings transcripts, and press releases); US government public sources (clinicaltrials.gov, FDA.gov, Orange Book); pharmaceutical industry databases; and published articles in scientific and medical journals.
•Revenue forecasting is performed using a robust, data-driven, bottom-up, patient-based approach. Marketed drugs and potential new entrants in Phase 3 of development and beyond are individually forecast, and aggregate figures are provided.
•Revenue from off-label usage is not included, but is accounted for in forecast models.

Key Findings

Current Market Landscape
•Since the introduction of Lucentis in 2006, vascular endothelial growth factor (VEGF) antagonists have become the clear choice in treatment for age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) due to their high efficacy and safety.
•By 2017, Genentech and Regeneron are expected to split the AMD, DME, and RVO segments with their VEGF inhibitors Lucentis and Eylea, respectively.
- In 2017, Lucentis and Eylea are each estimated to produce roughly $Xbillion in revenue.
- Eylea's favorable bi-monthly dosing has enabled Regeneron to be a viable competitor to Genentech's Lucentis. In 2014, Eylea's label will expand to include DME.
•Eylea and Lucentis are comparably priced; however, Avastin is available through compounding pharmacies at an immense discount, which significantly disrupts the branded AMD, DME, and RVO market. X to X% of the AMD, DME, and RVO segments are estimated to be off-label Avastin usage.
•Although new VEGF treatments are highly efficacious, they require intravitreal injections which is an invasive procedure. Thus, dosing frequency is a key determinant of market uptake.
•The AMD, DME, and RVO segments are set for continued growth due to an aging US population, and the DME segment in particular due to an increasing prevalence of diabetes.

Future Competitors
•There are more than 15 compounds in Phase 2 development and beyond.
•If approved, Allergan will have the first once-every-3-months VEGF inhibitor with AGN-150998, expected to launch in 2018 to 2019.
- If Phase 3 data shows comparable efficacy and safety to current VEGF inhibitors, Allergan has the potential to gain X% or more of the market due to its less frequent dosing.
•Ophthotec's platelet-derived growth factor (PDGF) inhibitor Fovista has the potential to become the first add-on therapy to VEGF inhibitors.
- This product has significant market potential due to a complementary rather than competitive add-on therapy strategy.
•New treatments that can be administered orally or topical drops would revolutionize treatment; however, it appears unlikely that any current pipeline medications will have comparable safety and efficacy profiles to current VEGF treatments.

Scope and Segmentation

Geographic Coverage: US
Study Period: 2009–2017
Base Year: 2012
Forecast Period: 2013–2017
Monetary Unit: US Dollars

•This research service evaluates the United States market for pharmaceutical treatments for the following retinal diseases: AMD, DME, and RVO.
•Units are defined as patients. Treated patient numbers, when estimated, are derived from annual sales revenue and annual cost of therapy.
•The price is the annual cost of therapy, and the average annual cost of therapy is based on the average wholesale price (AWP) per drug, as reported in Thomson Reuters Red Book. Hospital or clinic-associated expenses are not included in the cost of therapy.
•Indication-specific annual revenue, as reported, is used when available. Otherwise, estimates are used.

Key Questions This Study Will Answer

Is the market growing, how long will it continue to grow, and at what rate?
Are the existing competitors structured correctly to meet customer needs?
What pipeline candidates have the greatest potential? When are they expected to reach market?
Which treatments are set to dominate the market? How much market share for each competitor?
What is the peak sales potential for AMD, DME, and RVO market?
What the strengths and weaknesses of current and future therapies?

Table Of Contents

1. Executive Summary
2. Market Overview
3. Competitive Playbook
4. Total Retinal Therapeutics Market
• Drivers and Restraints
• Forecasts and Trends
5. Competitive Environment
6. AMD Segment Breakdown
7. DME Segment Breakdown
8. RVO Segment Breakdown
9. Key Companies to Watch
10. The Last Word
11. Appendix

List of Exhibits

• Total Retinal Therapeutics Market: Market Engineering Measurements, US, 2012
• Total Retinal Therapeutics Market: Market Segmentation, US, 2012
• Total Retinal Therapeutics Market: Game-changing Strategies, US, 2013
• Total Retinal Therapeutics Market: Key Market Drivers, US, 2012–2017
• Total Retinal Therapeutics Market: Key Market Restraints, US, 2012–2017
• Total Retinal Therapeutics Market: Market Engineering Measurements, US, 2012
• Total Retinal Therapeutics Market: Revenue Forecast, US, 2009–2017
• Total Retinal Therapeutics Market: Average Wholesale Price per Injection, US, 2009–2017
• Total Retinal Therapeutics Market: Competitive Landscape, US, 2013
• Total Retinal Therapeutics Market: Marketed Product Analysis, US, 2013
• Total Retinal Therapeutics Market: Pipeline Analysis, US, 2013
• Total Retinal Therapeutics Market: Absolute Market Share Trend by Revenue US, 2012 and 2017
• Total Retinal Therapeutics Market: Company Market Share Analysis of Top 4 Participants, US, 2012
• Total Retinal Therapeutics Market: SWOT Analysis, US, 2013
• Total Retinal Therapeutics Market: Timeline of Key Events, US, 2009–2017
• Total Retinal Therapeutics Market: Patent Expirations, US, 2000–2030
• Total Retinal Therapeutics Market, AMD Segment: Comparative Best Corrected Visual Acuity from Baseline for Select Marketed Drugs, US, 2012
• AMD Segment: Market Engineering Measurements, US, 2012
• AMD Segment: Revenue Forecast, US, 2009–2017
• AMD Segment: Prevalence and Treated Patient Forecast, US, 2009–2017
• AMD Segment: Penetration Analysis, US, 2009–2017
• DME Segment: Market Engineering Measurements, US, 2012
• DME Segment: Revenue Forecast, US, 2009–2017
• DME Segment: Prevalence and Treated Patient Forecast, US, 2009–2017
• DME Segment: Penetration Analysis, US, 2009–2017
• RVO Segment: Market Engineering Measurements, US, 2012
• RVO Segment: Revenue Forecast, US, 2009–2017
• RVO Segment: Prevalence and Treated Patient Forecast, US, 2009–2017
• RVO Segment: Penetration Analysis, US, 2009–2017

To order this report: Analysis of the US Retinal Therapeutics Market
http://www.reportlinker.com/p01936265/Analysis-of-the-US-Retinal-Therapeutics-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that the "First Containers & Microservices Conference" will take place June 9-11, 2015, at the Javits Center in New York City. The “Second Containers & Microservices Conference” will take place November 3-5, 2015, at Santa Clara Convention Center, Santa Clara, CA. Containers and microservices have become topics of intense interest throughout the cloud developer and enterprise IT communities.
Buzzword alert: Microservices and IoT at a DevOps conference? What could possibly go wrong? In this Power Panel at DevOps Summit, moderated by Jason Bloomberg, the leading expert on architecting agility for the enterprise and president of Intellyx, panelists will peel away the buzz and discuss the important architectural principles behind implementing IoT solutions for the enterprise. As remote IoT devices and sensors become increasingly intelligent, they become part of our distributed cloud en...
Can the spatial component of your Big Data be harnessed and visualized, adding another dimension of power and analytics to your data? In his session at Big Data Expo®, John Meza, Product Engineer and Performance Engineering Team Lead at Esri, discussed the spatial queries that can be used within the Hadoop ecosystem and their integration with GeoSpatial applications. The GIS Tools for Hadoop project was also discussed and its implementation to discover location-based patterns and relationships...
“We are strong believers in the DevOps movement and our staff has been doing DevOps for large enterprise environments for a number of years. The solution that we build is intended to allow DevOps teams to do security at the speed of DevOps," explained Justin Lundy, Founder & CTO of Evident.io, in this SYS-CON.tv interview at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Almost everyone sees the potential of Internet of Things but how can businesses truly unlock that potential. The key will be in the ability to discover business insight in the midst of an ocean of Big Data generated from billions of embedded devices via Systems of Discover. Businesses will also need to ensure that they can sustain that insight by leveraging the cloud for global reach, scale and elasticity.
You often hear the two titles of "DevOps" and "Immutable Infrastructure" used independently. In his session at DevOps Summit, John Willis, Technical Evangelist for Docker, will cover the union between the two topics and why this is important. He will cover an overview of Immutable Infrastructure then show how an Immutable Continuous Delivery pipeline can be applied as a best practice for "DevOps." He will end the session with some interesting case study examples.
Docker is becoming very popular--we are seeing every major private and public cloud vendor racing to adopt it. It promises portability and interoperability, and is quickly becoming the currency of the Cloud. In his session at DevOps Summit, Bart Copeland, CEO of ActiveState, discussed why Docker is so important to the future of the cloud, but will also take a step back and show that Docker is actually only one piece of the puzzle. Copeland will outline the bigger picture of where Docker fits a...
The 4th International Internet of @ThingsExpo, co-located with the 17th International Cloud Expo - to be held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA - announces that its Call for Papers is open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.
SYS-CON Media named Andi Mann editor of DevOps Journal. DevOps Journal is focused on this critical enterprise IT topic in the world of cloud computing. DevOps Journal brings valuable information to DevOps professionals who are transforming the way enterprise IT is done. Andi Mann, Vice President, Strategic Solutions, at CA Technologies, is an accomplished digital business executive with extensive global expertise as a strategist, technologist, innovator, marketer, communicator, and thought lea...
Announced separately, New Relic is joining the Cloud Foundry Foundation to continue the support of customers and partners investing in this leading PaaS. As a member, New Relic is contributing the New Relic tile, service broker and build pack with the goal of easing the development of applications on Cloud Foundry and enabling the success of these applications without dedicated monitoring infrastructure. Supporting Quotes "The proliferation of microservices and new technologies like Docker ha...
Even though it’s now Microservices Journal, long-time fans of SOA World Magazine can take comfort in the fact that the URL – soa.sys-con.com – remains unchanged. And that’s no mistake, as microservices are really nothing more than a new and improved take on the Service-Oriented Architecture (SOA) best practices we struggled to hammer out over the last decade. Skeptics, however, might say that this change is nothing more than an exercise in buzzword-hopping. SOA is passé, and now that people are ...
There is little doubt that Big Data solutions will have an increasing role in the Enterprise IT mainstream over time. 8th International Big Data Expo, co-located with 17th International Cloud Expo - to be held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA - has announced its Call for Papers is open. As advanced data storage, access and analytics technologies aimed at handling high-volume and/or fast moving data all move center stage, aided by the cloud computing bo...
"People are a lot more knowledgeable about APIs now. There are two types of people who work with APIs - IT people who want to use APIs for something internal and the product managers who want to do something outside APIs for people to connect to them," explained Roberto Medrano, Executive Vice President at SOA Software, in this SYS-CON.tv interview at Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
The 5th International DevOps Summit, co-located with 17th International Cloud Expo – being held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the...
Discussions about cloud computing are evolving into discussions about enterprise IT in general. As enterprises increasingly migrate toward their own unique clouds, new issues such as the use of containers and microservices emerge to keep things interesting. In this Power Panel at 16th Cloud Expo, moderated by Conference Chair Roger Strukhoff, panelists will address the state of cloud computing today, and what enterprise IT professionals need to know about how the latest topics and trends affec...